IMBrave150 (A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients with Untreated Locally Advanced or Metastatic HCC) was the first trial to demonstrate substantial improvement in OS associated with the combination of atezolizumab, the programmed cell death 1 ligand 1 (PD-L1) blocking antibody, and bevacizumab, the anti-vascular endothelial growth factor A antibody, compared with sorafenib. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.